1887

Journal of Medical Microbiology logo

Volume 71, Issue 5

Immunization with a bicistronic DNA vaccine modulates systemic IFN-γ and IL-10 expression against infection No Access

Abstract

Cholera is an acute enteric infection caused by , particularly in areas lacking access to clean water. Despite the global effort to improve water quality in these regions, the burden of cholera in recent years has not yet declined. Interest has therefore extended in the use of bicistronic DNA vaccine encoding and genes of as a potential vaccine.

The potential of a bicistronic DNA vaccine, pVAX- has not been determined and .

The goal of present study was to evaluate expression and potential of pVAX- vaccine against .

The pVAX- was transiently transfected into mammalian COS-7 cells, and the expression was assessed using fluorescence and Western blot analyses. Next, the vaccine was encapsulated into sodium alginate using water-in-oil emulsification and evaluated for its efficiency in different pH conditions. Subsequently, oral vaccination using en(pVAX-) was performed . The animals were challenged with O1 El Tor after 2 weeks of vaccination using the Removable Intestinal Tie-Adult Rabbit Diarrhoea (RITARD) model. Following the infection challenge, the rabbits were monitored for evidence of symptoms, and analysed for systemic cytokine expression level (TNF-α, IFN-γ, IL-6 and IL-10) using quantitative real-time polymerase chain reaction.

The expression of pVAX- was successfully verified via fluorescence and Western blot analyses. Meanwhile, analysis demonstrated that the en(pVAX-) was able to protect the RITARD model against infection due to a lack of evidence on the clinical manifestations of cholera following bacterial challenge. Furthermore, the bicistronic group showed an upregulation of systemic IFN-γ and IL-10 following 12 days of vaccination, though not significant, suggesting the possible activation of both T-helper 1 and 2 types of response. However, upon bacterial challenge, the gene expression of all cytokines did not change.

Our findings suggest that the bicistronic plasmid DNA vaccine, pVAX-, showed a potential role in inducing immune response against cholera through upregulation of gene and protein expression as well as cytokine gene expression, particularly IFN-γ and IL-10.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): alginate , bicistronic construct , cholera , DNA vaccine , microencapsulation and RITARD
© 2022 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001536
2022-05-30
2024-04-30
Loading full text...

Full text loading...

References

  1. Heidelberg JF, Eisen JA, Nelson WC, Clayton RA, Gwinn ML et al. DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. Nature 2000; 406:477–484
     [Google Scholar]
  2. Ali M, Lopez AL, You YA, Kim YE, Sah B et al. The global burden of cholera. Bull World Health Organ 2012; 90:209–218A
     [Google Scholar]
  3. Harris JB. Cholera: immunity and prospects in vaccine development. J Infect Dis 2018; 218:141–146
     [Google Scholar]
  4. Morris JG. Cholera and other types of vibriosis: A story of human pandemics and oysters on the half shell; 2003; 21201
  5. Almagro-Moreno S, Taylor RK. Cholera: environmental reservoirs and impact on disease transmission. Microbiol Spectr 2013; 1:1–19
     [Google Scholar]
  6. Rodo X, Pascual M, Fuchs G, Faruque ASG. ENSO and cholera: A nonstationary link related to climate change?. Proc Natl Acad Sci U S A 2002; 99:12901–12906 [View Article]
     [Google Scholar]
  7. Mandal S, Mandal MD, Pal NK. Cholera: A great global concern. Asian Pac J Trop Med [Internet] 2011; 4:573–580 [View Article]
     [Google Scholar]
  8. Bhowmick R, Ghosal A, Das B, Koley H, Saha DR et al. Intestinal adherence of Vibrio cholerae involves a coordinated interaction between colonization factor GbpA and mucin. Infect Immun 2008; 76:4968–4977
     [Google Scholar]
  9. Herrington DA, Hall RH, Losonsky G, Mekalanos JJ, Taylor RK et al. Toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med 1988; 168:1487–1492
     [Google Scholar]
  10. Finkelstein RA, LoSpalluto JJ. Pathogenesis of experimental cholera: preparation and isolation of choleragen and choleragenoid. J Exp Med 1969; 130:185–202
     [Google Scholar]
  11. Butler SM, Camilli A. Going against the grain: chemotaxis and infection in Vibrio cholerae. Nat Rev Microbiol 2005; 3:611–620
     [Google Scholar]
  12. Liang W, Wang S, Yu F, Zhang L, Qi G et al. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108. Infect Immun 2003; 71:5498–5504
     [Google Scholar]
  13. Kaper JB, Morris JG, Levine MM. Cholera. Clin Microbiol Rev 1995; 8:48–86
     [Google Scholar]
  14. Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet 2004; 363:223–333
     [Google Scholar]
  15. Mondal M, Nag D, Koley H, Saha DR, Chatterjee NS. The Vibrio cholerae extracellular chitinase ChiA2 is important for survival and pathogenesis in the host intestine. PLoS One 2014; 9:1–12
     [Google Scholar]
  16. Clemens JD, Harris JR, Khan MR, Kay BA, Yunus M et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986; 328:124–127
     [Google Scholar]
  17. Azman AS, Luquero FJ, Ciglenecki I, Grais RF, Sack DA et al. The impact of a one-dose versus two-dose oral cholera vaccine regimen in outbreak settings: A modeling study. PLoS Med 2015; 12:1–18 [View Article]
     [Google Scholar]
  18. Abdo Hasson SSA, Al-Busaidi JKZ, Sallam TA. The past, current and future trends in DNA vaccine immunisations. Asian Pac J Trop Biomed [Internet] 2015; 5:344–353 [View Article]
     [Google Scholar]
  19. Farris E, Brown DM, Ramer-tait AE, Pannier AK. Micro- and nanoparticulates for DNA vaccine delivery. Exp Biol Med 2016; 241:919–929
     [Google Scholar]
  20. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE et al. Clinical applications of DNA vaccines: current progress. Clin Infect Dis 2011; 53:296–302 [View Article]
     [Google Scholar]
  21. Wang S, Lu S. DNA immunization. Curr Protoc Microbiol 2013; 31:1–28
     [Google Scholar]
  22. Doria-rose NA, Haigwood NL. DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods 2003; 31:207–216
     [Google Scholar]
  23. Garver KA, LaPatra SE, Kurath G. Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon. Dis Aquat Organ 2005; 64:13–22
     [Google Scholar]
  24. Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the animal medical center. Vaccine 2006; 24:4582–4585
     [Google Scholar]
  25. Draghia-Akli R, Ellis KM, Hill LA, Malone PB, Fiorotto ML. High-efficiency growth hormone releasing hormone plasmid vector administration into skeletal muscle mediated by electroporation in pigs. FASEB J 2015; 17:526–528
     [Google Scholar]
  26. Syahril NA, Mariana NS, Sidhu HS, Rosli R. In vitro expression of the ctxB toxin gene towards the development of a DNA vaccine against cholera. Mol Biol Today 2002; 3:71–77
     [Google Scholar]
  27. Nograles N, Abdullah S, Shamsudin MN, Billa N, Rosli R. Formation and characterization of pDNA-loaded alginate microspheres for oral administration in mice. J Biosci Bioeng 2012; 113:133–140 [View Article]
     [Google Scholar]
  28. Gelber RH, Mehra V, Bloom B, Murray LP, Siu P et al. Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads. Infect Immun 1994; 62:4250–4255
     [Google Scholar]
  29. Cui T, Xiong J, Wang Y, Wen X, Huang X et al. Construction of an artificial recombinant bicistronic plasmid DNA vaccine against porcine rotavirus onderstepoort. J Vet Res 2013; 80:1–8
     [Google Scholar]
  30. Tian J, Sun X, Chen X. Formation and oral administration of alginate microspheres loaded with pDNA coding for lymphocystis disease virus (LCDV) to japanese flounder. Fish Shellfish Immunol 2008; 24:592–599
     [Google Scholar]
  31. Sone T, Nagamori E, Ikeuchi T, Mizukami A, Takakura Y et al. A novel gene delivery system in plants with calcium alginate micro-beads. J Biosci Bioeng 2002; 94:87–91
     [Google Scholar]
  32. Dobakhti F, Rahimi F, Dehpour AR, Taghikhani M, Ajdary S et al. Stabilizing effects of calcium alginate microspheres on mycobacterium bovis BCG intended for oral vaccination. J Microencapsul 2006; 23:844–854
     [Google Scholar]
  33. Rodrigues AP, Hirsch D, Figueiredo HCP, Logato PVR, Moraes AM. Production and characterisation of alginate microparticles incorporating Aeromonas hydrophila designed for fish oral vaccination. Process Biochem 2006; 41:638–643
     [Google Scholar]
  34. Spira WM, Sack RB, Froehlich JL. Simple adult rabbit model for Vibrio cholerae and enterotoxigenic Escherichia coli diarrhea. Infect Immun 1981; 32:739–747
     [Google Scholar]
  35. Bhowmick TS, Koley H, Das M, Saha DR, Sarkar BL. Pathogenic potential of vibriophages against an experimental infection with Vibrio cholerae O1 in the RITARD model. Int J Antimicrob Agents 2009; 33:569–573
     [Google Scholar]
  36. Espino AM, Rivera F. Quantitation of cytokine mRNA by real-time RT-PCR during a vaccination trial in a rabbit model of fascioliasis. Vet Parasitol 2010; 169:82–92
     [Google Scholar]
  37. Godornes C, Leader BT, Molini BJ, Centurion-Lara A, Lukehart SA. Quantitation of rabbit cytokine mRNA by real-time RT-PCR. Cytokine 2007; 38:1–7
     [Google Scholar]
  38. Kim TK. T test as a parametric statistic. Korean J Anesthesiol 2015; 68:540–546
     [Google Scholar]
  39. Rainczuk A, Scorza T, Spithill TW, Smooker PM. A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria. Infect Immun 2004; 72:5565–5573
     [Google Scholar]
  40. Santana VC, Diniz MO, Cariri F, Ventura AM, Cunha-Neto E et al. Bicistronic DNA vaccines simultaneously encoding HIV, HSV and HPV antigens promote CD8+ T cell responses and protective immunity. PLoS One 2013; 8:1–10
     [Google Scholar]
  41. Dirks W, Wirth M, Hauser H. Dicistronic transcription units for gene expression in mammalian cells. Gene 1993; 128:247–249
     [Google Scholar]
  42. Mizuguchi H, Xu Z, Ishii-watabe A, Uchida E. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 2000; 1:376–382 [View Article]
     [Google Scholar]
  43. Payne AJ, Gerdes BC, Kaja S, Koulen P. Insert sequence length determines transfection efficiency and gene expression levels in bicistronic mammalian expression vectors. Int J Biochem Mol Biol 2013; 4:201–208
     [Google Scholar]
  44. Kim TK, Eberwine JH. Mammalian cell transfection: the present and the future. Anal Bioanal Chem 2010; 397:3173–3178
     [Google Scholar]
  45. Lu B, Wen R, Yang H, He Y. Sustained-release tablets of indomethacin-loaded microcapsules: preparation, in vitro and in vivo characterization. Int J Pharm 2007; 333:87–94
     [Google Scholar]
  46. Wang C, Ge Q, Ting D, Nguyen D, Shen H et al. Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccine. Nat Mater 2004; 3:190–196
     [Google Scholar]
  47. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009; 30:23–32
     [Google Scholar]
  48. Storni T, Kundig TM, Senti G, Johansen P. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev 2005; 57:333–355
     [Google Scholar]
  49. O’Hagan DT, Rappuoli R. Novel approaches to pediatric vaccine delivery. Adv Drug Deliv Rev 2006; 58:29–51
     [Google Scholar]
  50. Johansen P, Storni T, Rettig L, Qiu Z, Der-sarkissian A et al. Antigen kinetics determines immune reactivity. Proc Natl Acad Sci U S A 2008; 105:5189–5194
     [Google Scholar]
  51. Leong J, Lam W, Ho K, Voo W, Lee M-X et al. Advances in fabricating spherical alginate hydrogels with controlled particle designs by ionotropic gelation as encapsulation systems. Particuology 2016; 24:44–60 [View Article]
     [Google Scholar]
  52. Caetano LA, Almeida AJ, Gonçalves LMD. Effect of experimental parameters on alginate/ chitosan microparticles for BCG encapsulation. Mar Drugs 2016; 14:1–30
     [Google Scholar]
  53. Vogel R, Pal AK, Jambhrunkar S, Patel P, Thakur SS et al. High-resolution single particle zeta potential characterisation of biological nanoparticles using tunable resistive pulse sensing. Sci Rep 2017; 7:1–13
     [Google Scholar]
  54. Chen S-C, Wu Y-C, Mi F-L, Lin Y-H, Yu L-C et al. A novel pH-sensitive hydrogel composed of N,O-carboxymethyl chitosan and alginate cross-linked by genipin for protein drug delivery. J Control Release 2004; 96:285–300 [View Article]
     [Google Scholar]
  55. Simsek-ege FA, Bond GM, Stringer J. Polyelectrolye complex formation between alginate and chitosan as a function of ph. J Appl Polym Sci 2003; 88:346–351
     [Google Scholar]
  56. Norris DA, Sinko PJ. Effect of size, surface charge, and hydrophobicity on the translocation of polystyrene microspheres through gastrointestinal mucin. J Appl Polym Sci 1996; 63:1481–1492
     [Google Scholar]
  57. Larhed AW, Artursson P, Gråsjö J, Björk E. Diffusion of drugs in native and purified gastrointestinal mucus. J Pharm Sci 1997; 86:660–665 [View Article]
     [Google Scholar]
  58. Mumper RJ, Hoffman AS, Puolakkainenb PA, Bouchardb LS, Gombotzb WR. Calcium-alginate beads for the oral delivery of transforming growth factor-B1 (TGF-B1): stabilization of TGF-B1 by the addition of polyacrylic acid within acid-treated beads. J Control Release 1994; 30:241–251
     [Google Scholar]
  59. Gombotz WR, Wee SF. Protein release from alginate matrices. Adv Drug Deliv Rev 1998; 31:267–285
     [Google Scholar]
  60. Kenney RT, Edelman R. Survey of human-use adjuvants. Expert Rev Vaccines 2003; 2:167–188 [View Article]
     [Google Scholar]
  61. Lund FE. Cytokine-producing B lymphocytes - key regulators of immunity. Curent Opin Immunol 2009; 20:332–338
     [Google Scholar]
  62. Nielsen AT, Otto G, Miller MC, Wu CY et al. RpoS controls the Vibrio cholerae mucosal escape response. PLoS Pathog 2006; 2:933–948
     [Google Scholar]
  63. Nielsen AT, Rasmussen T, Otto G, Miller MC et al. A bistable switch and anatomical site control Vibrio cholerae virulence gene expression in the intestine. PLoS Pathog 2010; 6:1–23
     [Google Scholar]
  64. Conner JG, Teschler JK, Jones CJ, Yildiz FH. Staying alive: Vibrio cholerae’s cycle of environmental survival, transmission, and dissemination. Microbiol Spectr 2017; 4:1–48
     [Google Scholar]
  65. Russell RG, Tall BD, Morris JG. Non-O1 Vibrio cholerae intestinal pathology and invasion in the removable intestinal tie adult rabbit diarrhea model. Infect Immun 1992; 60:435–442 [View Article]
     [Google Scholar]
  66. Sarkar M, Bhowmick S, Casola A, Chaudhuri K. Interleukin-8 gene regulation in epithelial cells by Vibrio cholerae: role of multiple promoter elements, adherence and motility of bacteria and host MAPKs. FEBS J 2012; 279:1464–1473 [View Article]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001536
Loading
Immunization with a bicistronic DNA vaccine modulates systemic IFN-γ and IL-10 expression against Vibrio cholerae infection
J. Med. Microbiol. 71, 001536 (2022); https://doi.org/10.1099/jmm.0.001536
/content/journal/jmm/10.1099/jmm.0.001536
/content/journal/jmm/10.1099/jmm.0.001536
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error